A little-known approach to infertility is complicating the White House's IVF push
By Aria Bendix,
NBC News
| 08. 08. 2025
President Donald Trump has nicknamed himself “the fertilization president,” but six months after he formally pledged to expand access to in vitro fertilization, the White House has yet to issue a policy to that end.
Since he campaigned on the issue last year, Trump’s push to support IVF has been complicated by backlash from conservatives and anti-abortion groups who see IVF as unethical, as well as members of the “Make America Healthy Again” movement who view the pharmaceutical industry as having undue influence over fertility care.
Many of these groups have instead suggested that Trump redirect his attention to a little-known holistic approach called restorative reproductive medicine. The underlying philosophy is that doctors can identify and treat the root causes of infertility, often with less invasive and more affordable methods than IVF.
But restorative reproductive medicine isn’t formally recognized as a medical specialty in the U.S. and has not been evaluated as extensively as IVF has. Many fertility doctors worry that holistic methods are being presented to patients as a better alternative to IVF, thereby denying patients access...
Related Articles
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...